Previous 10 | Next 10 |
Relief Therapeutics has a found a new use for Vasoactive Intestinal Peptide by repackaging it as RLF-100 (Aviptadil) to now fight COVID. RLF-100 is still undergoing clinical Phase 2/3 trials but has already shown promising use in an emergency setup for critically ill patients. In ...
Acceleron Pharma ([[XLRN]] -1.8%) announces new data from two Phase 2 clinical trials, SPECTRA and PULSAR, evaluating sotatercept in patients with pulmonary arterial hypertension ((PAH)).Preliminary results from 10 participants in SPECTRA showed that treated patients experienced substantial i...
PhaseBio Pharmaceuticals (PHAS): Q3 GAAP EPS of -$0.86 misses by $0.15.Cash and cash equivalents of $39.4MPress Release For further details see: PhaseBio Pharmaceuticals EPS misses by $0.15
Expanded pivotal Phase 3 REVERSE-IT trial of product candidate bentracimab (PB2452) for reversal of antiplatelet effects of ticagrelor into Canada and dosed first patients outside the United States Resuming enrollment in ongoing Phase 2b trial of pemziviptadil (PB1046) in pulm...
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular and cardiopulmonary diseases, today announced that Chief Executive Officer Jonathan P. Mow will participat...
PhaseBio Pharmaceuticals (PHAS) slips 5% in premarket on light volume, after it announced to discontinue VANGARD trial evaluating pemziviptadil (PB1046) as a treatment for hospitalized COVID-19 patients who are at high risk for rapid clinical deterioration and acute respir...
VANGARD trial discontinued due to evolving COVID-19 treatment landscape, recent feedback from FDA regarding regulatory and development path, and interim analysis of trial data Enrollment expected to resume for ongoing Phase 2b trial of pemziviptadil in pulmonary arterial hyper...
Thinly traded micro cap PhaseBio Pharmaceuticals (PHAS) up 4% in premarket, has expanded its Phase 3 REVERSE-IT trial for its lead product candidate bentracimab (PB2452) into Canada, where the first patients outside U.S. have now been enrolled and dosed.The Phase 3 RE...
Cardiovascular disease remains a leading cause of mortality in both Canada and globally; the lack of reversal agents for patients taking antiplatelet therapies who require urgent surgery or experience a major bleeding event remains a critical unmet need Bentracimab (PB2452) ha...
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular and cardiopulmonary diseases, today announced that Chief Executive Officer Jonathan P. Mow will present a company ...
News, Short Squeeze, Breakout and More Instantly...
PhaseBio Pharmaceuticals Inc. Company Name:
PHAS Stock Symbol:
NASDAQ Market:
Bidding Process and Auction Projected to Conclude December 2022 PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today announced that...
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today reported financial results for the second quarter ended June 30, 2022, and provided an upd...